Research Article

Metabolic syndrome and serum ferritin level in postmenopausal women in urban cities in Enugu State, Nigeria

Ekene E. Chukwukelu1*, Lawrence U. S. Ezeanya2, Jane E. Onyia-Pat3, Edwin N. Okafor1

1Department of Chemical Pathology, Faculty of Medical Sciences College of Medicine, University of Nigeria Teaching Hospital, Itukku/Ozalla, Enugu State, Nigeria
2Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria Nsukka, Enugu, Nigeria
3Department of Nursing, Faculty of Health Sciences and Technology, University of Nigeria, Enugu state, Nigeria

Received: 26 July 2016
Revised: 04 August 2016
Accepted: 13 August 2016

*Correspondence:
Dr. Ekene E. Chukwukelu
E-mail: ekene.chukwukelu@unn.edu.ng

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Physiological and biochemical changes that alter the general health of women are seen in menopause which include increase in adiposity and elevated serum ferritin. There is a dearth of information on the prevalence and common risk factors of MS and their association with iron stores of the body among postmenopausal women (POMW) in Enugu. Hence, this study was carried out to determine the prevalence of metabolic syndrome, the most prevalent components of metabolic syndrome and its relationship with serum ferritin level in postmenopausal women in Enugu, Nigeria.

Methods: The study was a cross sectional study, carried out from February to August 2013 among two hundred and twenty four (224) apparently healthy postmenopausal women aged 40 to 83 years. Metabolic syndrome was defined using National Cholesterol Education Programme, Adult Treatment Panel III criteria.

Results: The most frequent components of metabolic syndrome (MS) seen among the subjects were high waist circumference (WC) (70.1%), high blood pressure (66.5%) and low high density lipoprotein cholesterol (25.4%). The prevalence of metabolic syndrome among the women was 29.0% while the mean level of serum ferritin of subjects with metabolic syndrome showed no significant (p >0.05) difference when compared to subjects without MS.

Conclusions: The most frequent cluster of the risk factor of MS in the population studied was high WC, high blood pressure and low high density lipoprotein cholesterol (HDL). Although serum ferritin is slightly associated with FPG and WHR, it may not be used as diagnostic tool for MS in the group studied.

Keywords: Metabolic Syndrome, Ferritin, Postmenopausal women

INTRODUCTION

The health of girls and women is affected by developmental, psychological and physiological age. Women’s lives are marked by a continuous transition from intrauterine life, infancy, adolescence, menarche, reproductive life, menopausal transition, postmenopausal to the frail elderly life. Across the life span of a woman, menopause probably has the greatest impact on the health of women.1 Menopause is the phase of aging during which women passes from reproductive to non-reproductive stage.2 Oestrogen deficiency is a major occurrence in postmenopausal women and is associated with symptoms and diseases that are of increasing importance to women’s health. Physiological and biochemical changes that alter the general health of women are seen in menopause which includes an increase in adiposity, which is a risk factor for developing insulin
resistance, dyslipidaemia, breast cancer, hypertension and cardiovascular diseases.\textsuperscript{3,5} Also, due to cessation of menstruation, the iron store of the body increases, resulting in elevated serum ferritin which is the major iron storage compound in the body.\textsuperscript{6} Elevated serum ferritin has been associated with hypertension, hyperinsulinaemia, hyperglycaemia and central adiposity which are components of metabolic syndrome (MS).\textsuperscript{7-10} Metabolic syndrome can be defined as a cluster of metabolic abnormalities that occur together in an individual more often than is expected by chance and directly increase the risk of cardiovascular diseases, type 2 diabetes and other causes of morbidity and mortality. The abnormalities include: insulin resistance, obesity, hypertension, dyslipidaemia, glucose intolerance, prothrombotic and proinflammatary state.\textsuperscript{11} Metabolic syndrome is a cardiovascular risk factor of public health significance but there is a dearth of information on the most frequent of these risk factors of MS and their relationship with body iron stores measured as serum ferritin among the postmenopausal women in urban areas of Enugu state, Nigeria. Therefore, with the increase in the rate of morbidity and mortality among postmenopausal women in this locality, it is imperative to study the relationship between serum ferritin and metabolic syndrome in this group.

**METHODS**

**Study population**

The study was a cross sectional study, conducted in two urban centres (Enugu and Nsukka) in Enugu State, South East, Nigeria, from February to August, 2013. Two hundred and twenty-four (224) apparently healthy postmenopausal women aged 40 to 83 years who gave written informed consent, were recruited for the study. Awareness was created through different women groups and institutions while the research was carried out in Chemical Pathology Department College of Medicine University of Nigeria, Enugu Campus.

**Exclusion criteria**

Subjects on lipid lowering drugs, iron replacement therapy and those who received or donated blood within the past four months prior to the study were excluded.

**Inclusion criteria**

Apparently healthy Postmenopausal women, who reported absence of menstruation for one year or more, living in Enugu urban who gave written informed consent were included in the study.

**Ethical consideration**

Ethical approval was sought and obtained from the Ethics Committee of Enugu State Ministry of Health. Written informed consent was obtained from the respondents who met the inclusion criteria prior to the study. The right and welfare of the participant were observed as stated in the Helsinki declaration.\textsuperscript{12}

**Demographic data collection**

Questionnaire and oral interview were used to interview the women in order to elicit information on age, ethnicity, educational background, and menopausal status, history of blood donation or reception and medications.

**Anthropometric measurements**

The body weight, height, waist and hip circumferences were measured to the nearest 1 kg, 0.1 m, 0.1 cm, 0.1 cm respectively using standard protocols. The BMI was calculated as the ratio of body weight in kg to height in meter squared (kg/m\textsuperscript{2}). The blood pressure was measured and the reading taken in nearest one millimetre of mercury (1 mmHg) using sphygmomanometer.

**Blood sample collection and analysis**

Five millilitres of venous blood sample was collected from each subject after an overnight fast of 8-12 hours using a standard method. Two millilitres of the sample were placed in a fluoride oxalate bottle for the estimation of fasting plasma glucose while 8 ml was placed in a clean dry plain tube, and the serum separated after clotting. The serum was used to assay the levels of ferritin, triacylglycerol and high density lipoprotein cholesterol. Fasting plasma glucose concentration was determined using the glucose oxidase method.\textsuperscript{13} Serum triacylglycerol (TG) concentration was measured by enzymatic method while the concentration of high density lipoprotein cholesterol (HDLC) was measured using phosphotungstic acid precipitation and cholesterol oxidase method.\textsuperscript{14,15} Serum ferritin concentration was measured using solid phase enzyme linked immunosorbent assay (ELISA) based on sandwich principle.\textsuperscript{16} Commercially prepared kits by Teco USA were used to assay for glucose, triacylglycerol and high density lipoprotein cholesterol while ferritin was assayed using a commercially prepared kit by DRG, Germany.

**Diagnosis of metabolic syndrome**

An individual was identified as having metabolic syndrome if she presented with any three or more of these risk factors blood pressure (BP) ≥130/85 mmHg, waist circumference (WC) >88 cm, high density lipoprotein cholesterol (HDLC) <1.3 mmol/l, triacylglycerol (TG) ≥1.7 mmol/l and fasting plasma glucose (FPG) ≥5.6 mmol/l. This is the revised National cholesterol education programme adult treatment panel III criteria.\textsuperscript{17}

**Statistical analysis**

Statistical package for social sciences (SPSS) version 16 and graph pad prism software were used to analyze the
data obtained. The results were presented as mean±standard deviation for continuous variables while absolute numbers and percentages were used to present the categorical variables. Student’s t-test, Spearman correlation and ANOVA were used to compare the data and inferences made at 95% confidence limit (p <0.05).

RESULTS

Out of 224 subjects, 65 of them had three or more of the risk factors of MS giving a prevalence of 29%. According to the result in Table 1, the most frequent risk factor was central obesity measured as high WC (70.1%). It was followed by HBP and low HDLC while the least were high TAG and high FPG. The same pattern of cluster of the risk factors were seen when the subjects were grouped into the postmenopausal women with metabolic syndrome (POMW+MS) and those without (POMW-MS). Other measures of obesity, WHR and BMI recorded the highest prevalence of metabolic syndrome (POMW+MS). Although high FPG and TAG were the least frequent, subjects with high level of serum ferritin recorded the least prevalence for MS (34.6%).

Table 1: Frequency of the risk factors of metabolic syndrome in the groups studied.

| Variables | POMW (n=224) | POMW+MS (n=65) | POMW-MS (n=159) |
|-----------|--------------|----------------|-----------------|
| WC (cm)   | 157 (70.1)   | 64 (98.5)      | 93 (58.5)       |
| WHR       | 139 (62.1)   | 53 (81.5)      | 86 (54.1)       |
| BMI       | 76 (33.9)    | 40 (61.5)      | 36 (22.6)       |
| HBP       | 149 (66.5)   | 59 (90.8)      | 90 (56.6)       |
| TAG       | 21 (9.4)     | 15 (23.1)      | 6 (3.8)         |
| HDLC      | 57 (25.4)    | 42 (64.6)      | 15 (9.4)        |
| FPG       | 45 (20.1)    | 34 (52.3)      | 11 (6.9)        |

Abnormality was identified using revised NCEP ATP III criteria and frequency is expressed in absolute number and percentage. WC= waist circumference, WHR= waist to hip ratio, BMI= body mass index, HBP= high blood pressure, TAG= triacylglycerol, HDLC= high density lipoprotein cholesterol and FPG= fasting plasma glucose. POMW= postmenopausal women, POMW+MS= postmenopausal women with metabolic syndrome, POMW-MS= postmenopausal women without metabolic syndrome.

The mean values of WC, WHR, BMI, SBP, DBP, TAG and FPG were significantly (p <0.05) higher among the POMW+MS compared with the POMW-MS while that of the HDLC was significantly (p <0.05) lower among the POMW+MS.

The result in Table 3 which shows the prevalence of MS in subjects with high values of the parameters measured reveals that subjects with high fasting plasma glucose recorded the highest prevalence of metabolic syndrome (77.8%), this was followed by HDLC and TAG. Although high FPG and TAG were the least frequent abnormalities seen among the subjects, greater number of subjects with these abnormalities had MS. However, subjects with high level of serum ferritin recorded the least prevalence for MS (34.6%).

Table 2: Comparison of the means of all the parameters studied between the POMW+MS and POMW-MS.

| Variables      | POMW+MS (n=159) | POMW-MS (n=159) | P value |
|----------------|-----------------|-----------------|---------|
| Age (years)    | 56.1±1.10       | 54.9±0.63       | >0.05   |
| WC (cm)        | 100.8±1.12      | 90.18±0.90      | <0.05   |
| WHR            | 0.92±0.01       | 0.86±0.01       | <0.05   |
| BMI (kg/m²)    | 31.82±0.50      | 27.71±0.41      | <0.05   |
| SBP (mmHg)     | 144.80±2.56     | 133.2±1.72      | <0.05   |
| DBP (mmHg)     | 88.22±1.44      | 82.99±1.00      | <0.05   |
| TAG (mmol/L)   | 1.39±0.06       | 1.10±0.03       | <0.05   |
| HDLC (mmol/L)  | 1.23±0.03       | 1.55±0.03       | <0.05   |
| FPG (mmol/L)   | 6.41±0.33       | 4.80±0.11       | <0.05   |
| Ferritin (µg/l)| 96.57±8.38      | 93.42±5.72      | <0.05   |

Variables are as mean±standard error of mean.

Table 3: Prevalence of metabolic syndrome among subjects with various risk factors of metabolic syndrome and high serum ferritin level.

| Variables      | Abnormality n | MS + n (%) | MS – n (%) |
|----------------|---------------|------------|------------|
| WC (>88cm)    | 157           | 65 (41.4)  | 92 (58.6)  |
| WHR (>0.85)   | 139           | 53 (38.1)  | 86 (61.9)  |
| BMI (>30kg/m²)| 76            | 40 (52.6)  | 36 (47.4)  |
| HBP (>130/85mmHg) | 149     | 59 (37.1)  | 90 (60.4)  |
| TAG (>1.7mmol/L)| 21         | 15 (71.4)  | 6 (28.6)   |
| HDLC (>1.3mmol/L)| 57         | 42 (73.7)  | 15 (26.3)  |
| FPG (>6.6mmol/L)| 45         | 35 (77.8)  | 10 (22.2)  |
| Ferritin (>120µg/l)| 52    | 18 (34.6)  | 34 (65.0)  |

Revised NCEP ATP III criteria was used to identify abnormal variables and the frequency was expressed in number and percentage.

Subjects were grouped according to the number of risk factors acquired, those without any risk factors (0), those
with 1 to 2 number of risk factors (1-2) and those with ≥3 number of risk factors (≥3). One way analysis of variance was used to ascertain the effect of the increase in the number of risk factors of MS on the mean level of the biochemical parameters. The result as represented in Table 4 showed that mean levels of TAG and FPG increases significantly (p <0.05) and HDLC decreases significantly (p <0.05) with increase in the number of the risk factor while ferritin recorded no significant (p >0.05) variation with increase in the number of risk factors.

Table 4: Effect of increasing number of risk factors of MS on the mean level of the biochemical parameters measured.

| Variables   | 0 (n=17) | 1-2 (n=142) | ≥3 (n= 65) | P value |
|-------------|----------|-------------|------------|---------|
| TAG (mmol/L) | 0.85±    | 1.12±       | 1.39±      | P <0.05 |
| HDLC (mmol/L) | 0.07     | 0.03        | 0.06       |         |
| FPG (mmol/L)  | 4.41±    | 4.85±       | 6.41±      | P < 0.05|
| Ferritin (µg/l) | 70.41±   | 96.18±      | 96.57±     | P > 0.05|
| BMI (kg/m²)  | 0.084    | 0.174       | 0.008      | P >0.05 |
| WHR          | 0.008    | 0.302       | 0.32       | P > 0.05|
| SBP (mmHg)   | -0.062   | -0.084      | -0.064     | P > 0.05|
| TAG (mmol/L)  | 0.064    | 0.080       | 0.080      | P >0.05 |
| HDLC (mmol/L) | 0.175    | 0.080       | 0.080      | P <0.05 |

Variables are expressed as mean±standard error of mean.

Serum ferritin was correlated with the risk factors of MS and the result in Table 5 showed that values of serum ferritin showed significant weak correlation with only WHR (r= 0.174) and FPG (r= 0.175).

Table 5: Correlation of serum ferritin and risk factors of MS.

| Variables | r value | P value |
|-----------|---------|---------|
| WC (cm)   | 0.084   | P >0.05 |
| WHR       | 0.174   | P <0.05 |
| BMI (kg/m²) | 0.008  | P >0.05 |
| SBP (mmHg) | -0.062 | P >0.05 |
| DBP (mmHg) | -0.084 | P >0.05 |
| TAG (mmol/L) | 0.064  | P >0.05 |
| HDLC (mmol/L) | 0.080  | P >0.05 |
| FPG (mmol/L) | 0.175  | P <0.05 |

(r) Spearman correlation coefficient.

DISCUSSION

In this study, it was observed that the most frequent risk factor in this population was central obesity measured as high WC. This agrees with the result of the study conducted among the postmenopausal women in Brazil and Tehran but disagrees with the study conducted among POMW in Gorgan Iran in which low HDLC was reported as the most frequent. Although WHR and BMI were relatively high in this study, they were not as sensitive as WC in detecting central obesity. However, BMI may be more specific in identifying individual with MS as greater percentage of subjects with high BMI had MS. Increase in intra-abdominal fat is a common disorder associated with women in their menopausal stage and occurs in approximately 65% of all women. This is as a result of cellular changes that include increased lipoprotein lipase activity and decreased lipolysis those result from oestrogen deficiency and increased androgenicity.

Also, variation in socio-demographic factor, genetic predisposition and diet, may have contributed to the variation in the frequency of these risk factors. This can explain why this present work and that of Ulasi et al which was done in Enugu Eastern Nigeria recorded high WC as most frequent risk factor while the works of Adediran, Alebiosu and Odusan, Nwegbu and Jaiyesimi conducted in South western part of Nigeria recorded HBP as the most frequent risk factor. The most common cluster of risk factors (high WC, HBP and low HDLC) recorded in this study, is a common feature of most studies in Nigeria and some parts of Africa. However, studies in Saudi, recorded low HDLC, TAG, and WC as the most frequent cluster with HBP and FPG being the least frequent while among the Mexican-American, WC, TAG and FPG was the most frequent cluster. High fasting plasma glucose and TAG which were the least occurring risk factors in this study showed a higher specificity in identifying subjects with MS. The presence of high WC and low HDLC in the predominant cluster of risk factor among this group studied conforms to the fact that low oestrogen seen in postmenopausal women favours atherogenic dyslipidaemia (low HDLC) and preferential deposition of fat in the abdominal region. Some researchers in the Western world have associated high serum ferritin to the prevalence of MS and some of its risk factors like insulin resistance, hypertension, obesity, high FPG but in this study, ferritin recorded a very weak association with FPG and WHR and there was no significant difference in the mean values of ferritin of POMW+MS and POMW-MS. The research conducted among postmenopausal women in US and Korea reported a significantly higher level of ferritin among those with MS and demonstrated that ferritin level may predict MS.

The prevalence of MS (29%) recorded in this study is low compared to 31%, 31%, 32.6%, 33.7%, 41.5%, and 54.6% reported among POWM in Iran, Canada, China, Austria and Korea respectively. Decreasing oestrogen level and alteration of its ratio with testosterone has been implicated as a causal factor for the emergence of MS at menopausal transition. This results to preferential increase in intra-abdominal fat and atherogenic lipoprotein- lipid profile (low level of HDLC and high TAG) and these were very high risk for MS and consequently, type 2 diabetes, premature aging, cardiovascular diseases and some forms of cancer.
CONCLUSION

This study has determined that central obesity measured as WC was the most common risk factor of MS among POMW in Enugu urban and that the predominant cluster of risk factors for MS in this group is high WC, HBP and low HDLC. Although serum ferritin is slightly associated with FPG and WHR, it may not be used as diagnostic tool for MS in the group studied.

ACKNOWLEDGEMENTS

Authors would like to thank head of department of chemical pathology, college of medicine Itukku/Ozalla, where the analysis of this samples were performed

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Enugu state ministry of health

REFERENCES

1. Jian J, Pelle E, Huang X. Iron and Menopause. Does increased iron affect the health of postmenopausal women? Antioxidant and Redox Signaling. 2009;11(2):2939-43.
2. Shende SS, Iyer CM, Makajan VV, Chakole S, Kute P, Sonare A. Effect of duration on lipid profile status on postmenopausal women. The Health Agenda. 2004;2(3):90-4.
3. Poehlman ET, Tchernof A. Traversing the menopause: Changes in energy expenditure and body composition. Coronary Artery Disease. 1998;9(12):799-803.
4. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278(17):1407-11.
5. Achi LN, Olorunshola KV, TORYILA JE, Tender JA. The body mass index, waist circumference and blood pressure of postmenopausal women in Zaria, Northern Nigeria. Current Research Journal of Biological Sciences. 2012;4(3):329-32.
6. Cho SH. Serum ferritin and metabolic syndrome in perimenopausal and postmenopausal women. Journal of Korean Society on Menopause. 2011;17(13):166-173.
7. Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, et al. Increased serum ferritin is common in men with essential hypertension. Journal of Hypertension. 2002;20:1513-8.
8. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care. 2004;27:2422-8.
9. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men: The Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord. 2001;25:639-45.
10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735-52.
11. National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report. Circulation. 2002;106:3143-21.
12. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2000;284:3043–5.
13. Trinder P. Determination of blood glucose using 4-aminophenazone. Clin Path. 1969;22:246.
14. Mcgowan MW, Artiss JD, Strandergh DR, Zak BA. Peroxidase coupled method for the colorimetric determination of serum TG. Clin Chem. 1983;29:533-42.
15. Lopes-virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem. 1977;23:882-4.
16. Fairbank VF, Klee GG. Biochemical aspect of Hematology. In: Tietz Fundamentals of Clinical Chemistry, 4th Ed. Burtis, CA. and Ashwood, ER. Ed., Philadelphia. W.B.Saunders company; 1966:704-744.
17. Petri-Nahas EA, Padoani NP, Nahas-Neto J, Orsatti FL, Tarduo AP, Dias R. Women. Climacteric. 2009;12(5):431-8.
18. Jouyandeh Z, Nayebzadeh F, Qorbani M, Asadi M. Metabolic syndrome and menopause. Journal of Diabetes and Metabolic Disorders. 2013;12:1.
19. Marjani A, Moghasemi S. The metabolic syndrome among postmenopausal women in Gorgan. Int J Endocrinol. 2012;10:1155-61.
20. Paszkowski T, Klodnicka M. Hormonal Therapy of Menopause. Menopause. 2007;2:106-9.
21. Toth MJ, Sites CK, Eltabbakh GH, Poehlman MT. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care. 2000;23:801-6.
22. Ulasi II, Ijeoma CK, Onodugo OD. A community based study of hypertension and cardiometabolic syndrome in semi-urban and rural communities in Nigeria. Biomedical Central Health Services Research. 2010;10:71.
23. Adediran OS, Jimoh AK, Ogbera AO. Metabolic syndrome: Pathogenesis of its predictors. Postgraduate Doctors (Caribbean). 2008;22:35-45.
24. Alebiosu CO, Odusan BO. Metabolic syndrome in subjects with type 2 diabetes mellitus. J Natl Med Assoc. 2004;96:817-21.
25. Nwegbu MM, Jaiyesimi OO. Prevalence of metabolic syndrome amongst apparently healthy Nigerian adults in a hospital setting. Journal of Medicine and Medical Sciences. 2012;3(1):77-82.
26. Oladapo OO, Salako L, Shoyinka K, Adedapo K, Falase AO. Prevalence of cardiometabolic risk factors among a rural Yoruba South-Western Nigeria population: a population-based survey. Cardiovascular Journal of Africa. 2010;21(1):26-31.

27. Ogbera A. Prevalence and gender distribution of metabolic syndrome. Diabetology and Metabolic Syndrome. 2010;2:1-5.

28. Tran A, Gelaye B, Girma B, Lemma G, Berhane Y, Bekele T, et al. Prevalence of metabolic syndrome among working adults in Ethiopia. International Journal of Hypertension. 2011;1:8.

29. Gyaboko M, Amoah AG, Martey-Marbell A, Snow RC. Prevalence of the metabolic syndrome in rural population in Ghana. Biomedical Central Endocrine Disorders. 2012;12:25.

30. Bahijri SM, Raddadi RM. The importance local criteria in the diagnosis of metabolic syndrome in Saudi Arabia. Ther Adv in Endo and Metab. 2013;4(2):51-9.

31. Morris A, Ferdinand KC. Racial ethnic differences in lipid profiles. Clinical Lipidology. 2009;4(6):741-54.

32. Choi KM, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, et al. Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism. 2005;54(11):1510-4.

33. Ponholzer A, Temml C, Rauchenwald M, Marszalek M, Madersbacher S. Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women?. Int J Impot Res. 2008;20(1):100-4.

34. Ruan X, Jin J, Hua L, Liu Y, Wang J, Liu S. The prevalence of metabolic syndrome in Chinese postmenopausal women and the optimum body composition indices to predict it. Menopause. 2010;17(3):566-70.

35. Hidalgo LA, Chedraui PA, Morocho N, Alvarado M, Chavez D, Huc A. The metabolic syndrome among postmenopausal women in Ecuador. Gynecological Endocrinology. 2006;22(8):447–54.

36. Hee MK, Park J, So YR, Jongoh KIM. The effect of menopause on the metabolic syndrome among Korean women: the Korean National Health and Nutrition Examination Survey, 2001. Diabetes Care. 2007;30(3):701-6.

37. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and metabolic syndrome: the study of women’s health across the nation. Arch of Int Med. 2008;168:1568-75.

Cite this article as: Chukwukelu EE, Ezeanyika LUS, Onyia-Pat JE, Okafor EN. Metabolic syndrome and serum ferritin level in postmenopausal women in urban cities in Enugu State, Nigeria. Int J Sci Rep 2016;2(9):215-20.